What Protein Family Does Lipitor Target?
Lipitor (atorvastatin) targets the HMG-CoA reductase family. It inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, by competitively binding to its active site.[1]
How Does Lipitor Inhibit HMG-CoA Reductase?
Lipitor binds to the enzyme's substrate-binding pocket, mimicking HMG-CoA and preventing mevalonate production. This reduces hepatic cholesterol synthesis, upregulates LDL receptors, and lowers circulating LDL cholesterol by 40-60%.[1][2]
Why Is This Family Key to Cholesterol Control?
HMG-CoA reductase belongs to the short-chain dehydrogenase/reductase (SDR) superfamily, but statins like Lipitor specifically target its catalytic domain. No other major protein families are directly affected at therapeutic doses.[2]
What Happens If Lipitor Misses Its Target?
Off-target effects are rare but can include muscle toxicity (myopathy) from partial inhibition of other reductases or coenzyme Q10 depletion. Genetic variants in SLCO1B1 increase this risk.[3]
How Do Other Statins Compare in Targeting?
| Statin | Protein Family Targeted | Potency vs. Lipitor |
|--------|--------------------------|---------------------|
| Simvastatin (Zocor) | HMG-CoA reductase | Lower |
| Rosuvastatin (Crestor) | HMG-CoA reductase | Higher |
| Pravastatin | HMG-CoA reductase | Similar |
All statins hit the same family but differ in lipophilicity and half-life.[1][2]
When Did Lipitor's Patent Expire?
Lipitor's main composition patent (U.S. Patent 5,273,995) expired in 2011, allowing generics. Pediatric exclusivity added six months.[4]
[1]: DrugBank: Atorvastatin
[2]: PubMed: Mechanism of Statins
[3]: FDA Label: Lipitor
[4]: DrugPatentWatch: Lipitor Patents